Compare · LSTA vs SHC
LSTA vs SHC
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Sotera Health Company (SHC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and SHC operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- SHC is the larger of the two at $5.58B, about 341.9x LSTA ($16.3M).
- Over the past year, LSTA is down 27.3% and SHC is up 19.1% - SHC leads by 46.4 points.
- SHC has been more active in the news (9 items in the past 4 weeks vs 3 for LSTA).
- SHC has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Sotera Health Company
- Price
- $1.80+1.12%
- $19.54+0.10%
- Market cap
- $16.3M
- $5.58B
- 1M return
- +55.17%
- +10.02%
- 1Y return
- -27.27%
- +19.15%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 3
- 9
- Recent ratings
- 0
- 25
Sotera Health Company
Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Provides Update Following Termination of Merger Agreement
- Lisata Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events
- Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
Latest SHC
- Executive Chairman Petras Michael B. Jr. sold $21,174,786 worth of shares (1,144,515 units at $18.50), decreasing direct ownership by 43% to 397,912 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Leadership Update
- President of Sterigenics Rutz Michael P sold $2,825,250 worth of shares (150,000 units at $18.84), decreasing direct ownership by 31% to 334,279 units (SEC Form 4)
- Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,316 shares, decreasing direct ownership by 5% to 217,304 units (SEC Form 4) (tax liability)
- SEC Form 144 filed by Sotera Health Company
- SEC Form 10-Q filed by Sotera Health Company
- Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
- Sotera Health Announces Second-Quarter 2026 Earnings Release Date